StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Nalbuphin

Nalbuphine

HCID 5311304
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
20594-83-6
Standard-SMILES
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
InChIKey
NETZHAKZCGBWSS-CEDHKZHLSA-N
Summenformel
C21H27NO4
Durchschnittliche Molmasse
357,4 g/mol
Monoisotopische Masse
357,19400834

Überblick

Nalbuphine is an organic heteropentacyclic compound. It has a role as an opioid analgesic and a mu-opioid receptor antagonist. It derives from a hydride of a morphinan.

Namen und Bezeichner

Bevorzugter Name
Nalbuphine
IUPAC
(4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol
Lokaler Name
Nalbuphin
Englischer Name
nalbuphine
Summenformel
C21H27NO4
Molmasse
357.45

Namen und Synonyme

nalbuphine20594-83-6NalbufinaNalbuphinumIntapanDTXSID8023345L2T84IQI2KN-Cyclobutylmethyl-4,5alpha-epoxy-3,6alpha,14-morphinantriolCHEBI:7454DTXCID103345(4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,7,9-triol17-(Cyclobutylmethyl)-4,5alpha-epoxymorphinan-3,6alpha,14-triol
Weitere Namen anzeigen
C07251NALBUPNINENalbuphinebase2H3]-NalbuphineNaltrexoneImpurity24NETZHAKZCGBWSS-CEDHKZHLSA-NNalbuphine (1.0mg/ml in Acetonitrile)Nalbuphine (base and/or unspecified salts)17-[Cyclobutylmethyl]-4,5α-epoxymorphinan-3,6α,14-triolMorphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5α,6α)- (9CI)
Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5alpha,6alpha)-(1S,5R,13R,14S,17S)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo(9.6.1.0^(1,13).0^(5,17).0^(7,18))octadeca-7,9,11(18)-triene-10,14,17-triol(1S,5R,13R,14S,17S)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18)-triene-10,14,17-triol(4R,4aS,7S,7aR,12bS)-3-(cyclobutylmethyl)-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro(3,2-e)isoquinoline-4a,7,9-triolRefChem:57230(1S,5R,13R,14S,17S)-4-(cyclobutylmethyl)-12-oxa-4-azapentacyclo(9.6.1.01,13.05,17.07,18)octadeca-7,9,11(18)-triene-10,14,17-triol243-901-6Nalbuphine (INN)

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
0,2
Polarare Oberfläche (TPSA)
73,2 Ų
H-Brücken-Donoren
3
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
2
Schwere Atome
26
Formalladung
0
Komplexität
597

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

DEA NFLIS-Drug Category -> Narcotic Analgesics

Pharmaceuticals -> Listed in ZINC15

LogP1.4
Solubility2.09e+00 g/L
Human DrugsPharmaceuticals
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point230 °C (hydrochloride salt)
Physical DescriptionSolid
Dissociation Constants8.71 and 9.96 (hcl form)
Collision Cross Section189.51 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P270, P271, P301+P317, P304+P340, P317, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 5 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

TreatmentThe immediate intravenous administration an opiate antagonist such as naloxone or nalmefene is a specific antidote. Oxygen, intravenous fluids, vasopressors and other supportive measures should be used as indicated. (L1712)
Health EffectsMedical problems can include congested lungs, liver disease, tetanus, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose.
Adverse Effects · 1 Eintrag

The most common adverse effects following nalbuphine administration include sedation, sweating, nausea, vomiting, dizziness, vertigo, dry mouth, and headache. Anaphylactic, anaphylactoid, or severe hypersensitivity reactions have been reported in patients receiving nalbuphine, and immediate supportive medical treatment should be provided should they occur.

Exposure RoutesIntravenous. The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

N - Nervous system

QN - Nervous system

Protein BindingNot appreciably bound.
Pharmacodynamics · 1 Eintrag

Nalbuphine is a synthetic opioid agonist-antagonist analgesic of the phenanthrene series. Nalbuphine's analgesic potency is essentially equivalent to that of [morphine] on a milligram basis. The opoioid antagonist activity of nalbuphine is about one-fourth to that of [nalorphine] and 10 times to that of [pentazocine]. Nalbuphine by itself has potent opioid antagonist activity at doses equal to or lower than its analgesic dose. When administered following or concurrent with mu agonist opioid analgesics (e.g., morphine, oxymorphone, fentanyl), nalbuphine may partially reverse or block opioid-induced respiratory depression from the mu agonist analgesic. Nalbuphine may precipitate withdrawal in patients dependent on opioid drugs. Nalbuphine should be used with caution in patients who have been receiving mu opioid analgesics on a regular basis.

Mechanism of Action · 1 Eintrag

The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a partial mu antagonist analgesic, with some binding to the delta receptor and minimal agonist activity at the sigma receptor.

Biological Half-LifeThe plasma half-life of nalbuphine is about 5 hours.
Metabolism/MetabolitesHalf Life: The plasma half-life of nalbuphine is 5 hours, and in clinical studies the duration of analgesic activity has been reported to range from 3 to 6 hours.
FDA Pharmacological Classification · 6 Einträge

L2T84IQI2K

Zugehörige Reaktionen

8
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 39327
HRID 39327als Produkt
Reaktionsgleichung von HRID 533702
HRID 533702als Produkt
Reaktionsgleichung von HRID 533703
HRID 533703als Edukt
Reaktionsgleichung von HRID 1015685
HRID 1015685als Produkt
Reaktionsgleichung von HRID 1289465
HRID 1289465als Edukt
Reaktionsgleichung von HRID 1289466
HRID 1289466als Edukt
Reaktionsgleichung von HRID 1975972
HRID 1975972als Edukt
Reaktionsgleichung von HRID 2390904
HRID 2390904als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
20594-83-6
PubChem CID
5311304
DTXSID
DTXSID8023345
ChEMBL
CHEMBL895
ChEBI
CHEBI:7454
UNII
L2T84IQI2K
EC Number
243-901-6
Nikkaji
J14.212C
Schmelzpunkt
230.5 ° · 230.5°
Siedepunkt
566.6 · 566.6±50.0 °C(Predicted)
Dichte
1.44 · 1.44±0.1 g/cm3(Predicted)
Löslichkeit
soluble in Methanol
Aggregatzustand
Solid
pka
9.39 · 9.39±0.60(Predicted)
Farbe
White
Toxicity Summary · 2 Einträge

Signs and Symptoms of Overdose

Receptor studies show that nalbuphine exerts its action via binding to mu, kappa, and delta receptors, but not to sigma receptors. Nalbuphine is primarily a kappa agonist/partial mu antagonist analgesic. The exact mechanism of action is unknown, but is believed to interact with an opiate receptor site in the CNS (probably in or associated with the limbic system). The opiate antagonistic effect may result from competitive inhibition at the opiate receptor, but may also be a result of other mechanisms. Nalbuphine is thought primarily to be a kappa agonist. It is also a partial mu antagonist analgesic, with some binding to the delta receptor and minimal agonist activity at the sigma receptor.

Signs and SymptomsSymptoms of overdose include primarily sleepiness and mild dysphoria.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

nalbuphine

DILI Negative

Intravenous

DOI:10.1016/j.drudis.2019.09.022

Toxicity DataLD50: 1100 mg/kg (Oral, Dog) (A308)

Sicherheitsdaten

Alarmwort
Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302

NALBUPHINE

Mechanisms of Action [MoA] - Competitive Opioid Antagonists

Established Pharmacologic Class [EPC] - Opioid Agonist/Antagonist

Mechanisms of Action [MoA] - Partial Opioid Agonists

Nalbuphine is an Opioid Agonist/Antagonist. The mechanism of action of nalbuphine is as a Competitive Opioid Antagonist and Partial Opioid Agonist.

MeSH Pharmacological ClassificationCompounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS.
Absorption, Distribution and Excretion · 1 Eintrag

The mean absolute bioavailability was 81% and 83% for the 10 and 20 mg intramuscular doses, respectively, and 79% and 76% following 10 and 20 mg of subcutaneous nalbuphine. Clinical studies show that the duration of analgesic activity of the drug can range from 3 to 6 hours.

Cellular LocationsMembrane
Metabolite PathwaysNalbuphine Action Pathway

Verwendung und Herstellung

Uses · 1 Eintrag

Nalbuphine is indicated for the relief of moderate to severe pain. It can also be used as a supplement to balanced anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia during labor and delivery. [Wikipedia]

Use ClassificationPharmaceuticals

Anwendungen

VerwendenNalbuphine is a mixed opioid agonist-antagonist. Nalbuphine is an analgesic (narcotic).

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

CyclobutancarbonylchloridLithium Aluminum Hydride(5α)-4,5-Epoxy-3,14-dihydroxymorphinan-6-onhydrochlorid6α-Noroxymorphol(Bromomethyl)cyclobutane6-Keto Nalbuphine(5α)-4,5-Epoxy-3,14-dihydroxymorphinan-6-onCyclobutanecarboxaldehyde

Nachgelagerte Produkte

NALBUPHINE(5α,6α)-17-(Cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triolhydrochlorid